AGP Picks
View all

Massachusetts Weekly
Provided by AGP

Massachusetts Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

Press releases published on May 15, 2026

Walker’s Gymnastics & Dance Captures Massachusetts State Championship, Signaling New Era of Growth in Lowell
May 15, 2026

Walker’s Gymnastics & Dance Captures Massachusetts State Championship, Signaling New Era of Growth in Lowell

Indeterminate EIN Presswire
OXEIA BIOPHARMACEUTICALS NAMED MOST INNOVATIVE mTBI COMPANY 2026
May 15, 2026

OXEIA BIOPHARMACEUTICALS NAMED MOST INNOVATIVE mTBI COMPANY 2026

Indeterminate EIN Presswire
Vibesies Launches AI-Native Hosting Platform Built Around Vibe Coding
May 15, 2026

Vibesies Launches AI-Native Hosting Platform Built Around Vibe Coding

Indeterminate EIN Presswire
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
May 15, 2026

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

Indeterminate GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
AiFChem Enhances Drug Discovery as a Reliable Innovative Chiral Building Blocks Solution Provider
May 15, 2026

AiFChem Enhances Drug Discovery as a Reliable Innovative Chiral Building Blocks Solution Provider

Indeterminate EIN Presswire
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
May 15, 2026

Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu

Indeterminate GlobeNewswire
AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
May 15, 2026

AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment

Indeterminate GlobeNewswire
Flywire Continues Execution on Buyback Plan Through Direct Repurchase Agreement
May 15, 2026

Flywire Continues Execution on Buyback Plan Through Direct Repurchase Agreement

Indeterminate GlobeNewswire
Lifeward Reports First Quarter 2026 Financial Results
May 15, 2026

Lifeward Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
ELECTRA AI and Iron Horse Acquisition II Corp. (Nasdaq: IRHO) Announce Filing of Registration Statement on Form S-4 with the SEC in Connection with their Proposed Business Combination
May 15, 2026

ELECTRA AI and Iron Horse Acquisition II Corp. (Nasdaq: IRHO) Announce Filing of Registration Statement on Form S-4 with the SEC in Connection with their Proposed Business Combination

Indeterminate GlobeNewswire
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Indeterminate GlobeNewswire
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
May 15, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Indeterminate GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Massachusetts Weekly

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.